Abstract Submission

Late-Breaking Abstract Submission is Now Closed

Abstracts are in review and notifications will be sent the week of December 18.

Access Portal

Important Dates

Tuesday, August 1 - Thursday, November 9 Regular Abstract Submission (No Extension)
Friday, November 10 - Thursday, November 30 NEW! Late-Breaking Abstract Submission
Week of December 18 Notification of Abstracts

NEW! Late-Breaking Abstract Submission

Friday, November 10 – Thursday, November 30 (Now Closed)

ACTRIMS is seeking up to four (4) abstracts for oral platform presentation during the newly added Late-Breaking Research and Clinical Trials session on Saturday, March 2 and encourages submissions with promissory results or recent research findings, especially if these are of high clinical impact, i.e. clinical trials. This session is not CE-accredited, and ACTRIMS welcomes submissions from commercial interests/industry.

Selection of these abstracts for platform presentation during the Late-Breaking Research and Clinical Trials session will be highly competitive. If not selected for platform presentation, the submitted abstract will NOT be included in poster form in the ACTRIMS Forum 2024 program.

Please note: Late-Breaking Abstract Submission is NOT an extension of Regular Abstract Submission.

Regular Abstract Submission

Tuesday, August 1 - Thursday, November 9 (Now Closed)

ACTRIMS encourages the submission of abstracts on any research or clinical topic related to MS and other neuroimmunological disorders. Abstracts should contain original scientific material, including results of research studies, case descriptions, case series, and protocol design, not published or presented at the time of submission. Abstracts containing review of existing literature and opinion/editorials will not be accepted.

Abstracts are NOT restricted to studies that fall under the theme of this year’s Forum. Similarly, abstracts selected for oral platform presentations in the “Emerging Concepts in MS” or “Cutting Edge Developments” sessions will not be restricted by the theme of the Forum.

Abstract Preparation

  1. Abstracts must be submitted online via the abstract submission site. Abstracts submitted by email or fax will not be accepted.

  2. Titles must be submitted in title case, e.g. “Safety of New MS Therapies.”

  3. The abstract text contains five mandatory sections: background, objectives, methods, results, and conclusions. The full abstract text must be more than 100 characters but may not exceed 2500 characters, excluding spaces.

  4. A primary keyword must be selected during the abstract submission process (see list below).

  5. Abstracts should contain original material not published or presented at the time of submission.

  6. Abstracts must be submitted in English. Please use American English spelling.

  7. All abbreviations must be defined the first time they appear in the text, e.g. Multiple Sclerosis Impact Scale (MSIS). Do not define abbreviations in the title.

  8. Use the abstract submission site functions for Greek letters, mathematical symbols, special characters, and formatting. Avoid complex mathematical formulae.

  9. Use generic drug names.

  10. Tables, charts, or other graphics may not be included.

+ Keywords

  • Artificial Intelligence
  • Biomarkers
  • Big Data and Bioinformatics
  • Biostatistical Methods
  • Clinical Outcome Measures
  • Clinical Trials
  • Comorbidities
  • Infections including COVID-19
  • Diagnostic Criteria and Differential Diagnosis
  • Disease Modifying Therapies – Mechanism of Action
  • Disease Modifying Therapies – Risk Management
  • Epidemiology
  • Experimental Models
  • Gender Differences, Hormones and Sex Chromosomes
  • Genetics and Epigenetics
  • Imaging
  • Internet and Social Media
  • Network Science
  • Metabolomics
  • Microbiome
  • Neuromyelitis Optica and Anti-MOG Disease
  • Neuro-Ophthalmology
  • Neuroprotection, Regeneration and/or Remyelination
  • Neuropsychology and Cognition
  • Observational Studies
  • Pathogenesis – Immunology
  • Pathogenesis – Neurodegeneration
  • Pathogenesis – Role of Glia
  • Pathogenesis – Blood-Brain Barrier
  • Patient-Reported Outcomes and Quality of Life
  • Pediatric MS
  • Prognostic Factors
  • Real World Evidence
  • Rehabilitation and Comprehensive Care
  • Reproductive Aspects and Pregnancy
  • Symptom Management

+ Requirements for Continuing Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Interstate Postgraduate Medical Association (IPMA) and ACTRIMS. IPMA is accredited by ACCME to provide continuing education (CE) for physicians.

The rules governing eligibility of scientific meetings for CE are complicated and continually evolving, in particular, the rules related to submissions involving commercial interests (as defined by ACCME). Please note the following policies concerning abstracts for this meeting, some of which may differ from those of other scientific meetings you may have attended.

Abstracts accepted for oral platform presentation, for which CE credits will be offered, will be designated as such and will be clearly distinguished from non-CE work. For your submission to be included in a session that meets the requirements for AMA Category I credit and adheres to ACCME guidelines, it must meet each of the following criteria:

  1. No author may be an employee of a commercial interest, except under certain very specific circumstances that will require prior approval by our joint sponsors.
  2. The abstract, presentation, or slides may not be written, prepared, or produced by a commercial interest.
  3. The submission must be non-promotional in nature.
  4. The content must be appropriate in depth and scope for the intended physician audience.
  5. All presenting authors must complete and sign the disclosure form.

CE will not be offered for poster presentations or the Late-Breaking Research and Clincial Trials Session.

+ Abstracts with Authors Employed by Commercial Interests

Abstracts with authors who are employees of commercial interests, including abstracts solely from commercial interests, will be considered for non-CE sessions or poster presentations.

Abstracts reporting results from collaborative research conducted by both independent investigators (academic, clinician, and/or scientist) and investigators who are employees of commercial interests will not be accepted unless the independent investigators are included as authors.

+ Submission Limit per Author

There is no limit to the number of abstracts that an author can submit. All abstracts submitted will be reviewed by the Scientific Review Committee.

+ Review & Notification

Each abstract will be reviewed by at least 3 external experts. Each reviewer will receive author name(s) and affiliation(s) along with the abstract. Upon completion of the external review, the final decision of acceptance or rejection will be made by the Program Committee.

Notification of acceptance or rejection of submitted abstracts will be sent to presenting authors via email December 2023.

+ Embargo & Publication of Abstracts

All accepted abstracts will be published in the ACTRIMS Forum 2024 Abstract Catalog and the Multiple Sclerosis Journal online.

  • Full text of Regular Abstracts are embargoed until published on Monday, February 19, 2024.
  • Full text of Cutting Edge Development Abstracts are embargoed until published on Thursday, February 29, 2024.
  • Full text of Late-Breaking Abstracts are embargoed until published on Saturday, March 2, 2024.

+ Registration

The presenting author of an accepted abstract must register and attend the ACTRIMS Forum 2024. The presenter registration deadline is Wednesday, February 7, 2024. Presenters who do not register by the deadline will be dropped from the program. Please note that all presenters are responsible for their own registration expenses.

+ Withdrawing an Abstract

An accepted abstract should be withdrawn only under extraordinary circumstances. If you are unable to find a replacement presenter and must withdraw your presentation, please notify Keri Lore at klore@actrims.org by Monday, January 29, 2024.

+ Social Media Policy

Distributing news and information about ACTRIMS Forum 2024 through social media is encouraged within the embargo restrictions. Please use the official hashtag in all social media posts: #ACTRIMSForum